Press release
Psoriasis Biosimilars Market Key Players Analysis- Merck KGaA, Coherus BioSciences, Gyros Protein Technologies AB, Fresenius Kabi, Viatris, Amgen Inc.
Psoriasis Biosimilars Market
According to the latest research by InsightAce Analytic, the Psoriasis Biosimilars Market is valued at US$ 8.5 billion in 2023, and it is expected to reach US$ 19.3 billion by 2031, with a CAGR of 10.9% during the forecast period of 2024-2031.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2891
A biologic therapy is designated as a biosimilar when it demonstrates high similarity to an FDA-approved reference product used in the treatment of psoriasis. Psoriasis is a chronic autoimmune skin disorder marked by rapid skin cell proliferation, inflammation, and scaling. Following the expiration of patents on originator biologics, biosimilars are developed to adhere to stringent regulatory standards concerning safety, efficacy, and quality.
The global psoriasis biosimilars market is experiencing notable growth, primarily driven by the increasing prevalence of psoriasis and the growing demand for cost-effective therapeutic alternatives. Additionally, heightened awareness among healthcare professionals and patients regarding the clinical effectiveness and affordability of biosimilars is significantly contributing to their broader adoption and market expansion.
List of Prominent Players in the Psoriasis Biosimilars Market:
• Merck KGaA
• Coherus BioSciences
• Gyros Protein Technologies AB
• Fresenius Kabi
• Viatris
• Amgen Inc
• Samsung Bioepis Co., Ltd.
• Hoffmann-La Roche Ltd
• Celltrion
• Pfizer Inc.
• Samsung Bioepis
• Sandoz
• Novartis International AG
• Reddy's Laboratories
• GenScript
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02
Market Dynamics
Drivers:
The escalating costs of healthcare are prompting the adoption of biosimilars as cost-effective alternatives to originator biologics, offering comparable therapeutic efficacy at reduced prices. This shift has proven particularly beneficial for psoriasis patients, as biosimilars have shown effectiveness in symptom management and quality-of-life improvement. Payers and healthcare providers are increasingly inclined toward these more affordable solutions. Moreover, growing efforts to enhance healthcare accessibility in developing economies are further boosting demand. Government-backed initiatives promoting the use of biosimilars, especially in regions with a high prevalence of psoriasis, are accelerating market penetration. Additionally, the rising number of biosimilar approvals by regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) is reinforcing market growth.
Challenges:
One of the key challenges facing the psoriasis biosimilars market is regulatory uncertainty associated with product development, approval, and commercialization. Inconsistencies in regulatory frameworks, evolving guidelines, and complexities in proving biosimilarity and interchangeability present significant hurdles. These factors create an unpredictable environment that can delay product launches and limit patient access to cost-effective therapies, thereby hindering the market's full potential.
Regional Trends:
North America is projected to maintain a dominant position in the psoriasis biosimilars market, supported by its advanced biotechnology infrastructure and leadership in pharmaceutical innovation. Concurrently, the Asia-Pacific region is emerging as a high-growth area, driven by increased investment in biopharmaceutical R&D and the adoption of cutting-edge technologies for biosimilar development. The region's substantial psoriasis burden is contributing to rising demand for effective and affordable treatments, positioning biosimilars as essential components in the management of chronic dermatological conditions.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2891
Recent Developments:
• In July 2023, Coherus introduced YUSIMRYTM, a biosimilar of Humira®, priced at $995 per carton in the United States. YUSIMRY, sanctioned by the United States Food and Drug Administration (FDA) in 2021, is a tumour necrosis factor (TNF) inhibitor indicated for alleviating the signs and symptoms of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis, as well as for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.
Segmentation of Psoriasis Biosimilars Market-
By Drug Class-
• TNF-alpha inhibitors
o Infliximab
o Etanercept
o Adalimumab
• Other biosimilars
By Route of Administration-
• Subcutaneous
• Intravenous
• Oral
• Topical
By Indication-
• Plaque psoriasis
• Psoriatic arthritis
• Other types
By Distribution Channel-
• Hospital pharmacies
• Retail pharmacy chains
• Online pharmacies
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa
Read Overview Report- https://www.insightaceanalytic.com/report/psoriasis-biosimilars-market/2891
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Psoriasis Biosimilars Market Key Players Analysis- Merck KGaA, Coherus BioSciences, Gyros Protein Technologies AB, Fresenius Kabi, Viatris, Amgen Inc. here
News-ID: 4072018 • Views: …
More Releases from Insightace Analytic Pvt Ltd.
Animal Drug Compounding Market Deep Research Report with Forecast to 2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Animal Drug Compounding Market Size, Share & Trends Analysis Report By Animal Type (Companion Animals, Livestock Animals), By Product (Anti-infective Agents, Anti-inflammatory Agents, Hormones & Substitutes, CNS Agents, GI Drugs), By Route of Administration (Oral, Injectable, Topical), By Dosage Form (Suspensions, Solutions, and Capsules)- Market Outlook And Industry Analysis 2034"
The global Animal Drug Compounding market…
Artificial Intelligence (AI) In Dental Imaging Market for Personalized Treatment …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Artificial Intelligence (AI) In Dental Imaging Market Size, Share & Trends Analysis Report By Vehicle (Light commercial vehicles, Medium commercial vehicles, Heavy commercial vehicles), Fuel Cell Technology (Proton exchange membrane, Alkaline fuel cells, Solid oxide fuel cells), Range (Short-range, Medium-range, Long-range), End User (Public transit, Construction and mining, Logistics & transportation, Others)- Market Outlook And…
AI-Enhanced Minimally Invasive Devices Market Market Drivers, Challenges, and Op …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global AI-Enhanced Minimally Invasive Devices Market Size, Share & Trends Analysis Report By Product Type (AI-Enhanced Catheters, AI-Powered Endoscopy Systems, Robotic-Assisted Surgical Systems, Imaging and Visualization Devices, Other Devices), Application (Cardiology, Gastroenterology, Interventional Radiology, Orthopedics, Urology and Gynecology, Others), End User (Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics), Technology (Machine Learning, Computer Vision, Natural Language Processing…
AI in Pharmacovigilance Market Reducing Operational Costs and Enhancing Accuracy
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global AI in Pharmacovigilance Market Size, Share & Trends Analysis Report By Component (Software, Services), Deployment (On-premises, Cloud-based), End User (Pharmaceutical and Biotech Companies, Contract Research Organizations (CROs), Others) -Market Outlook And Industry Analysis 2034"
Global AI in Pharmacovigilance Market Size is predicted to grow at an 14.6% CAGR during the forecast period for 2025-2034.
Get Free Access…
More Releases for Psoriasis
Prevalence Of Psoriasis Driving Market Growth: A Key Catalyst Accelerating Psori …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Psoriasis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
Over the recent years, there has been a robust growth in the size of the psoriasis market. It is estimated to rise from $26.45 billion in 2024 to $28.93 billion in 2025, with a compound annual…
Psoriasis Vulgaris Market
Introduction
Psoriasis vulgaris, also known as plaque psoriasis, is the most common form of psoriasis, accounting for nearly 80-90% of all cases. It is a chronic autoimmune condition marked by red, scaly plaques that can cause significant physical discomfort and emotional distress. Affecting millions worldwide, psoriasis vulgaris is increasingly recognized as both a dermatological and systemic disease due to its association with arthritis, cardiovascular disease, and metabolic syndrome.
The global psoriasis vulgaris…
Major Growth Driver Identified in 2025 Psoriasis Market: Prevalence Of Psoriasis …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Psoriasis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent times, the size of the psoriasis market has experienced a significant increase. It is projected to escalate from $26.56 billion in 2024 to $29.5 billion in 2025, reflecting a compound annual growth rate (CAGR)…
Prevalence Of Psoriasis Driving Market Growth: Key Factor Driving The Growth In …
The Psoriasis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Psoriasis Market Size During the Forecast Period?
The psoriasis market has seen rapid growth in recent years. It will increase from $26.56 billion in 2024 to $29.5 billion in 2025, at a…
Plaque Psoriasis to Hold 85% Share of Psoriasis Drugs Market through 2031
Psoriasis is a chronic inflammatory skin disease that occurs due to genetic disposition and environmental factors. Psoriasis is a systemic disease associated with psychological, metabolic, arthritic, and cardiovascular comorbidities. On an average, psoriasis affects around 2 - 3% of the population globally.
Plaque psoriasis, being the number one and most common indication, held nearly 85% share of the US$ 11.37 Bn psoriasis drugs market in 2021, with the market estimated to…
Global Psoriasis Market with Focus on Plaque Psoriasis: Outlook to 2020
Psoriasis is a chronic inflammatory skin disease primarily causing scaling and inflammation of skin, characterized by sharply demarcated, scaly, red skin lesions most often on the elbows, knees, scalps, hands and feet. It occurs when the body’s immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis has been majorly classified into Plaque psoriasis, Guttate psoriasis, Inverse psoriasis, Pustular psoriasis and Erytherodermic psoriasis. It…
